Status:
COMPLETED
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
Lead Sponsor:
Eli Lilly and Company
Conditions:
Lung Cancer
Eligibility:
All Genders
45+ years
Phase:
PHASE2
Brief Summary
To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient bet...
Eligibility Criteria
Inclusion
- Sputum atypia participants with normal sputum cytology will be removed from the study)
- Metaplasia or dysplasia on at least one bronchoscopy specimen
- History of cigarette smoking ≥30 Pack Years
- Quit smoking ≥1 year prior to study entry
- Able to undergo bronchoscopy and helical computed tomography (CT) scanning of the chest
- Able to swallow tablets
Exclusion
- Blood clotting abnormalities
- Current smoking within the past 1 year
- Unwillingness to abstain from smoking while enrolled in the clinical trial or unwillingness to avoid significant second hand smoke exposure
- Evidence for lung cancer or carcinoma in situ
- Active cardiovascular disease
- Current illicit drug or alcohol abuse
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00414960
Start Date
December 1 2007
End Date
September 1 2010
Last Update
September 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tampa, Florida, United States, 33612